Goldilocks Therapeutics
Bedford · Founded 2018
About Goldilocks Therapeutics
Goldilocks Therapeutics develop preventatives treatments for acute kidney injury, polycystic kidney disease, and other kidney conditions. The company uses its proprietary mesoscale nanoparticles (MNPs) specifically target therapeutic payloads to the renal tubule epithelium. It was founded in 2018 and is based in Bedford, New York.
Company Facts
- Founded: 2018
- Legal name: Goldilocks Therapeutics, Inc.
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Funding stage: Seed
- Last round: Seed (Jan 2020)
- Website: goldilockstherapeutics.com
- Phone: (914) 205-3862
Canonical: https://fsome.com/organization/goldilocks-therapeutics-8345175 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.